| Bioactivity | EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain[1]. | ||||||||||||
| In Vivo | EC5026 (BPN-19186) has already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses[1]. | ||||||||||||
| Name | EC5026 | ||||||||||||
| CAS | 1809885-32-2 | ||||||||||||
| Formula | C18H23F4N3O3 | ||||||||||||
| Molar Mass | 405.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019. |
EC5026
CAS: 1809885-32-2 F: C18H23F4N3O3 W: 405.39
EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 s
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.